• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Rev Invest Clin . IMPACT OF COMORBIDITIES IN MEXICAN SARS-COV-2-POSITIVE PATIENTS: A RETROSPECTIVE ANALYSIS IN A NATIONAL COHORT

tetano

Editor, Senior Moderator
Rev Invest Clin


. 2020;72(3):151-158.
doi: 10.24875/RIC.20000207.
IMPACT OF COMORBIDITIES IN MEXICAN SARS-COV-2-POSITIVE PATIENTS: A RETROSPECTIVE ANALYSIS IN A NATIONAL COHORT


Ashuin Kammar-Garc?a[SUP] 1 2 [/SUP], Jos? de J Vidal-Mayo[SUP] 1 [/SUP], Juan M Vera-Zertuche[SUP] 3 [/SUP], Mart?n Lazcano-Hern?ndez[SUP] 4 [/SUP], Obdulia Vera-L?pez[SUP] 4 [/SUP], Orietta Segura-Badilla[SUP] 5 [/SUP], Patricia Aguilar-Alonso[SUP] 4 [/SUP], Addi R Navarro-Cruz[SUP] 4 [/SUP]



Affiliations

Abstract

Background: The coronavirus disease 2019 outbreak is a significant challenge for health-care systems around the world.
Objective: The objective of the study was to assess the impact of comorbidities on the case fatality rate (CFR) and the development of adverse events in patients positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the Mexican population.
Materials and methods: We analyzed the data from 13,842 laboratory-confirmed SARS-CoV-2 patients in Mexico between January 1, 2020, and April 25, 2020. We investigated the risk of death and the development of adverse events (hospitalization, pneumonia, orotracheal intubation, and intensive care unit [ICU] admission), comparing the number of comorbidities of each patient.
Results: The patient mean age was 46.6 ? 15.6 years, 42.3% (n = 5853) of the cases were women, 38.8% of patients were hospitalized, 4.4% were intubated, 29.6% developed pneumonia, and 4.4% had critical illness. The CFR was 9.4%. The risk of hospitalization (odds ratio [OR] = 3.1, 95% confidence interval [CI]: 2.7-3.7), pneumonia (OR = 3.02, 95% CI: 2.6-3.5), ICU admission (OR = 2, 95% CI: 1.5-2.7), and CFR (hazard ratio = 3.5, 95% CI: 2.9-4.2) was higher in patients with three or more comorbidities than in patients with 1, 2, or with no comorbidities.
Conclusions: The number of comorbidities may be a determining factor in the clinical course and its outcomes in SARS-CoV-2-positive patients.

Keywords: Adverse events; Comorbidities; Coronavirus disease 2019; Demographic characteristic; Mortality; Severe acute respiratory syndrome coronavirus 2.
 
Back
Top Bottom